Admitting that dealing with fake drugs is an uphill task, Chinese authorities said this week that they would take at least five years to stamp the menace out. China has imposed stringent penalties on makers of fake medicines, in the wake of severe international criticism.
India is part of this sordid story as well—both at home and outside. Indeed, just last month, a report by the European Commission identified it as the number one source for counterfeit drugs entering the EU, and ranked the UAE and China just behind it. Oversight, as we know, in both China and India is at its weakest on this front. Mint has been highlighting the menace for several months now. We were glad to note Union health minister A. Ramadoss promising us last week that he will act fast on the law concerned.
Several years have been wasted since the Mashelkar report came out. We urge the government to take action in the coming Parliament session, not just make it an exercise in rhetoric.